Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients

Bibliographic Details
Main Authors: Martin Adriana, Schellenberg Robert
Format: Article
Language:English
Published: BMC 2012-11-01
Series:Allergy, Asthma & Clinical Immunology
id doaj-f0c87a82af544d8b9040cdbf79dd78a4
record_format Article
spelling doaj-f0c87a82af544d8b9040cdbf79dd78a42020-11-25T01:34:27ZengBMCAllergy, Asthma & Clinical Immunology1710-14841710-14922012-11-018Suppl 1A1910.1186/1710-1492-8-S1-A19Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patientsMartin AdrianaSchellenberg Robert
collection DOAJ
language English
format Article
sources DOAJ
author Martin Adriana
Schellenberg Robert
spellingShingle Martin Adriana
Schellenberg Robert
Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
Allergy, Asthma & Clinical Immunology
author_facet Martin Adriana
Schellenberg Robert
author_sort Martin Adriana
title Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_short Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_full Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_fullStr Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_full_unstemmed Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
title_sort evaluation of safety and efficacy of a 20% subcutaneous immunoglobulin (hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
publisher BMC
series Allergy, Asthma & Clinical Immunology
issn 1710-1484
1710-1492
publishDate 2012-11-01
work_keys_str_mv AT martinadriana evaluationofsafetyandefficacyofa20subcutaneousimmunoglobulinhizentraafteradoseequivalentswitchfromintravenousorsubcutaneousreplacementtherapyinacohortofprimaryimmunodeficientpatients
AT schellenbergrobert evaluationofsafetyandefficacyofa20subcutaneousimmunoglobulinhizentraafteradoseequivalentswitchfromintravenousorsubcutaneousreplacementtherapyinacohortofprimaryimmunodeficientpatients
_version_ 1725071993136480256

Similar Items